Stock Track | TG Therapeutics Surges 5% as Positive BRIUMVI Data Set for Presentation at AAN 2025
TG Therapeutics Inc. (NASDAQ: TGTX) saw its shares soar 5% in pre-market trading on Friday, following the company's announcement of an upcoming schedule of presentations highlighting data on its drug BRIUMVI® (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS).
The data presentations, which will take place at the American Academy of Neurology (AAN) 2025 annual meeting from April 5-9 in San Diego, will showcase various aspects of BRIUMVI's efficacy and safety profile, as well as real-world observational data on the drug's use in MS patients.
Highlights of the presentations include long-term follow-up data from the ULTIMATE I and II Phase 3 trials, which evaluated BRIUMVI in patients with RMS over a 96-week period. Additionally, results from the ENHANCE Phase 3b study, assessing a modified BRIUMVI treatment regimen, will also be presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available